Renovaro Regains Compliance with NASDAQ Listing Requirement
Renovaro (NASDAQ: RENB), a company focused on AI-powered cancer diagnostics and therapeutics, has announced its successful compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq's Listing Qualifications Department that it has met the minimum $1.00 per share requirement under Rule 5550(a)(2). This resolves the previous notification received on September 12, 2024, when RENB's closing bid price had fallen below the required threshold for 30 consecutive business days. The company's shares will continue to trade on the Nasdaq Capital Market.
Renovaro (NASDAQ: RENB), una società focalizzata sulla diagnostica e terapia contro il cancro potenziata dall'IA, ha annunciato di aver rispettato con successo il requisito di prezzo minimo per le offerte di Nasdaq. La società ha ricevuto conferma dal Dipartimento delle Qualifiche per la Quotazione di Nasdaq di aver soddisfatto il requisito minimo di $1.00 per azione secondo la Regola 5550(a)(2). Ciò risolve la precedente comunicazione ricevuta il 12 settembre 2024, quando il prezzo di offerta di chiusura di RENB era sceso al di sotto della soglia richiesta per 30 giorni lavorativi consecutivi. Le azioni della società continueranno a essere scambiate sul Nasdaq Capital Market.
Renovaro (NASDAQ: RENB), una empresa centrada en diagnósticos y terapias contra el cáncer impulsadas por IA, ha anunciado su cumplimiento exitoso con el requisito de precio mínimo de oferta de Nasdaq. La empresa recibió la confirmación del Departamento de Calificaciones de Cotización de Nasdaq de que ha cumplido con el requisito mínimo de $1.00 por acción bajo la Regla 5550(a)(2). Esto resuelve la notificación previa recibida el 12 de septiembre de 2024, cuando el precio de oferta de cierre de RENB había caído por debajo del umbral requerido durante 30 días hábiles consecutivos. Las acciones de la empresa continuarán negociándose en el Nasdaq Capital Market.
Renovaro (NASDAQ: RENB)는 AI 기반의 암 진단 및 치료에 집중하는 회사로, 나스닥의 최저 호가 가격 요건을 성공적으로 준수했다고 발표했습니다. 회사는 나스닥 상장 자격 부서로부터 5550(a)(2) 규칙에 따라 주당 $1.00의 최소 요건을 충족했다는 확인을 받았습니다. 이는 RENB의 종가가 30일 연속으로 요구되는 기준 이하로 떨어졌던 2024년 9월 12일에 대한 이전 통지를 해결합니다. 회사의 주식은 나스닥 자본 시장에서 계속 거래될 것입니다.
Renovaro (NASDAQ: RENB), une entreprise axée sur le diagnostic et les thérapies contre le cancer alimentés par l'IA, a annoncé avoir satisfait avec succès à l'exigence de prix minimum des offres de Nasdaq. L'entreprise a reçu la confirmation du département des qualifications de cotation de Nasdaq qu'elle avait satisfait à l'exigence minimale de 1,00 $ par action selon la règle 5550(a)(2). Cela résout la notification précédente reçue le 12 septembre 2024, lorsque le prix de clôture de RENB avait chuté en dessous du seuil requis pendant 30 jours ouvrables consécutifs. Les actions de l'entreprise continueront à être négociées sur le Nasdaq Capital Market.
Renovaro (NASDAQ: RENB), ein Unternehmen, das sich auf KI-gestützte Krebsdiagnostik und -therapien konzentriert, hat seine erfolgreiche Einhaltung der Mindestangebotspreisanforderung von Nasdaq bekannt gegeben. Das Unternehmen erhielt die Bestätigung der Abteilung für Listing-Qualifikationen von Nasdaq, dass es die Mindestanforderung von $1,00 pro Aktie gemäß Regel 5550(a)(2) erfüllt hat. Dies löst die zuvor erhaltene Benachrichtigung vom 12. September 2024, als der Schlusskurs von RENB an 30 aufeinander folgenden Geschäftstagen unter die erforderliche Schwelle gefallen war. Die Aktien des Unternehmens werden weiterhin am Nasdaq Capital Market gehandelt.
- Regained Nasdaq listing compliance, eliminating delisting risk
- Maintained Nasdaq Capital Market listing status
- Previously failed to maintain minimum $1.00 share price requirement for 30 consecutive days
Insights
The company has successfully maintained a closing bid price above
However, investors should note that while regaining compliance removes a significant overhang, the underlying business fundamentals that led to the initial price decline need careful evaluation. Companies that face listing compliance challenges often experience recurring issues unless they demonstrate sustainable operational improvements. The resolution of this compliance matter provides Renovaro breathing room to focus on its AI-driven cancer diagnostics and therapeutics development without the distraction of potential delisting concerns.
LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule, 5550(a)(2). The Company’s security will continue to be listed and traded on The Nasdaq Stock Market and this matter is now closed.
Renovaro previously received a notification letter from the Nasdaq Listing Qualifications Department on September 12, 2024, notifying the Company that, over the previous 30 consecutive business days, the closing bid price of the Company’s common stock had been below the minimum of
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and Renovaro Cube.
Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@Renovaro Cube.com and STarsh@Renovarogroup.com
FAQ
What did Renovaro (RENB) announce regarding its Nasdaq listing status on December 20, 2024?
When did Renovaro (RENB) receive the initial Nasdaq non-compliance notice?
What is the minimum bid price requirement for Renovaro (RENB) to maintain Nasdaq listing?
How long was Renovaro (RENB) trading below the minimum bid requirement before receiving the notice?
